Zydus Lifesciences earnings calls.
Other · 2 quarters tracked · source-linked performance, management guidance and promise context.
Latest revenue
₹8,017 Cr
verified financial record
Quarters tracked
2
source records in the directory
Delivery assessment
0
Across 4 tracked commitments: 0 delivered, 4 missed.
Call date
2026-07-14
latest available source date
Signal trajectory
2 actual quartersCurrent read
0/100
Across 4 tracked commitments: 0 delivered, 4 missed.
Latest source read
What changed this quarter?
Zydus Lifesciences delivered a strong Q1 FY27 with 22% YoY revenue growth to ₹8,022 crore, driven by broad-based outperformance across India formulations (+20%), international markets (+34%), and consumer wellness (+67%). EBITDA margin of 24.1% reflects robust profitability despite incremental investments in specialty pipeline. The US specialty business now contributes 10% of revenue and is on track to exceed 15% by year-end. Key catalysts ahead include Saroglitazar's US launch (FY28), the Associo acquisition contributing $15-20M quarterly run-rate, and biosimilar scale-up. Management guides to 24%+ EBITDA margins for FY27 despite SRO investments, while targeting 28-30% margins over a 5-year horizon as branded revenue mix shifts beyond two-thirds. Key risks include SRO launch costs weighing on near-term margins, currency headwinds in North America, and competitive pressure in the US generics segment.
Colored figures compare against the previous available record. Hover or focus one for the comparison.
Signal
Positive
Revenue
₹8,017 Cr
Source date
2026-07-14
Across the record
Quarter history.
History modules